The tool on apoptosis in oncology also assists in analyzing the vast amount of strategic possibilities that have emerged in apoptotic drug development for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future.

Analysis of leukemia business development enables tracking cutting edge companies, therapies and new technologies. Analysis of key areas of pharmaceutical R&D helps identify emerging leukemia products. The tool is designed in a way to assist in finding right partners, optimizing licensing deals and choosing projects that give the best competitive advantage.

Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012, comprising Aventis Taxotere (docetaxel), Bristol-Myers Squibbs Paraplatin (carboplatin) and Eli Lillys Gemzar (gemcitabine). The third-generation chemotherapeutic agents have expanded the therapeutic options in the treatment of advanced lung cancer. However, despite their contributions, science has reached a therapeutic plateau.

The launch of Protease Inhibitors (PIs) accelerated the pace of innovation and impressive Sustained Virologic Response (SVR) rates by oral IFN free drug combinations. Freedom from IFN, treating all genotypes and vaccines could bring a sea of change in the HCV therapy class area in the future. Roche set the trend with the acquisition of Anadys for total of USD 230 mn followed by GILD buying VRUS for USD 11 bn, Bristol-Myers Squibb (BMY) acquiring Inhibitex for USD 2.5 bn, VRTX acquiring Virochem in 2009 for USD 375 mn, In-licensed Alios VX-135 in 2012 for total of USD 775 mn and Abbott in-licensed Enantas ABT-450 for total of USD 310 mn.

Unmet needs in hematologic malignancies calls for companies focusing on PI3Ks and BTK inhibitors to offer better treatment options. Around USD 10 bn has already been invested in licensing and acquisition of PI3K and other kinase inhibitors since the last five years. Targeting kinases have been on the agenda of most drug developers as they hold the key path to signaling, development and growth of the cell. Large global pharma are constantly on the hunt for drugs with label expansion potential, longevity and blockbuster potential.

Analytical tools to analyses antibodies and peptides in oncology lead to analyzing the vast amount of strategic possibilities that have emerged in R&D and business development in the antibody and peptide cancer drug competitive landscape. A progress analysis on current and emerging drugs for cancer antibodies in oncology lays down a comprehensive framework for further analysis of the field.

A progress analysis on current and emerging drugs on the peptide drug development the reveals promising investment opportunities. Popular products included in the package are Cancer Peptides: From First-in-Class to Best-in-Class; and Peptides in Oncology Drug Pipeline Update 2013.

Treating refractory hematological malignancies unfold a host of competition and commercial opportunities. Approved therapies for AML, MDS, unmet need and limitations of the current SOC for relapsed and refractory pts attract swarming competition. There is severe competition amongst the companies to launch new therapies for this indication. Companies leading in the race to launch such therapies include Ambit Biosciences, Onconova Therapeutics, SymBio Pharma, and Celgene.

The global touchless sensing equipment market is anticipated to grow at a CAGR of 32.2% over 2012 to 2016. The global touchless sensing equipment market has also been witnessing rapid technological advancement. However, touchless sensing equipment is not 100% accurate which could pose a challenge to the growth of this market. Growing need for high-level security in the government sector is set to drive the global touchless sensing equipment market.

The global vitamin D testing market is expected to grow at a CAGR of 32.36% over 2013 to 2018. One of the key factors contributing to this market growth is the increase in aging and chronically ill populations worldwide. This market has also been witnessing the increase in product approvals.

This report, the IT Market in Russia 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the IT market in Russia landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market. The key vendors dominating this space include ASUSTek Computer Inc., Hewlett Packard Co., IBM Corp., and National Computer Corp.

Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation. The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.

This report, the LTE Market in the US 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the LTE market in the US landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The non-existence of effective vaccine against HCV leads the healthcare market in United States to be driven by therapeutics. Vertexs Incivek was amongst the first DAA HCV therapies launched in the US and is the current market leader. Inciveks improved efficacy over the previous standard of care in the treatment of the most prevalent HCV genotype in the US, HCV GT1, which enabled the drug to quickly capture the market. Adverse events associated with Incivek therapy, such as life-threatening skin reactions, and the slow-progressing nature of HCV, has resulted in many patients deciding to forego treatment in order to wait for the launch of a more-tolerable HCV regimen.

The main growth driver for personal accident and health insurance during 2008 to 2012 was the launch of HIV or AIDS insurance by both health and life insurers, which was purchased by a large number of the country's formerly uninsured population. The personal accident and health insurance segment grew at a CAGR of 10.7% during 2008 to 2012. This robust growth was supported by the country's increasing per capita income levels, GDP growth, favorable insurance reforms, and financial and healthcare service expansions.

This report provides the results for the Soy Products market in China from Canadeans unique, highly detailed study of consumers Consumer Packaged Goods (CPG) consumption habits, and forms part of an overall series covering all CPG product markets. Its coverage includes, but is not limited to, consumption behaviors, the extent to which consumer trends influence their consumption, the value of the market these trends influence, and brand and private label choices as well as retailer choices.

Current market situation and trends unveil the future prospects of the electronic component market in Singapore to 2017. Important product segments include cards incorporating a magnetic stripe, cards incorporating an electronic integrated circuit, electrical capacitors, electrical resistors, potentiometers and rheostats, electronic integrated circuits and micro-assemblies, electronic printed circuits, semiconductor devices, thermionic and cold cathode valves and tubes.

Analysis of the power market scenario in Saudi Arabia in addition to an in-depth study of the active thermal power plants in the country, upcoming thermal installation details, and major equipment market size and company snapshots of some of the major market participants provides a future outlook of the industry with forecasts up to 2025. Key policies and regulatory framework supporting thermal power development assist in identifying key growth and investment opportunities in Saudi Arabia thermal power market. Company snapshots of some of the major market participants in the country facilitate understanding and responding to competitors business structure, strategy and prospects.

Although the maturity of the UK ready meals market has resulted in static growth in terms of sales value between 2007 and 2012, it is forecasted to grow significantly at a CAGR of 4.7%, between 2012 and 2017. In recent years, much attention has been paid to cooking becoming more common among men: it is no longer viewed as a chore and is more often considered as a life-skill akin to having a successful career, one that can enhance a person's image. However, while this is indeed true to an extent, UK males are still more reliant on ready meals than women. Despite social shifts, and a dominant media presence that has overstated their impact, women are still typically more likely to take on traditional roles within the family home, such as looking after the dietary habits of children and cooking.

The retail market in Hong Kong remains a high-potential market, with a CAGR of 8.08% expected between 2012 and 2017. It is predicted that by 2017, the retail market will continue to steadily increase and reach HKD 557.6 billion. Value Retailers are set to contribute to the growth in Hong Kong's retailing market. Hong Kong's retail market is set for healthy growth over the next four years, with a CAGR of 7.84% forecast between 2012 and 2017, which will see the market ultimately valued at HKD 18,466.3 million.